Microsoft word - algorithm of np-updated 05-04.doc

Algorithm for Chronic Pain (by Mode of Action) Proposed Mode of Action
Therapeutic Category
Medication
Alpha II-Agonist
Hypotensive
Alpha II-Agonist
Hypotensive
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anesthetic
AMPA-Na Channel Blocker
Anesthetic
Anti-inflammatory
Corticosteroid
Anti-inflammatory
Anti-inflammatory
Anti-inflammatory
Anti-inflammatory
Calcium Channel Blocker
Hypotensive
Gaba Agonist
Muscle Relaxant
Gaba Agonist
Benzodiazepine
Increase Blood Flow
Hemorheologic
Mu Agonist
Antidiarrheal
Mu Agonist
Mu Agonist
NMDA-Ca Channel Blocker
Antitussive
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Muscle Relaxant
Substance P
Analgesic
Supplements
Antiarthritic
Supplements
Antiarthritic
Supplements
Antoxidant
Supplements
Analgesic
Supplements
Analgesic
Supplements
Muscle Relaxant
Supplements
Muscle Relaxant
Supplements
Anti-inflammatory
Supplements
Analgesic
Supplements
Analgesic Synergy
Tricyclic Antidepressant
Antidepressant
Tricyclic Antidepressant
Antidepressant
Tricyclic Antidepressant
Antidepressant
Notes: Ketamine 5%, Gabapentin 10%, Clonidine 0.2%, Baclofen 2% is standard starting regimen. (Formula # 7919)
References:
1.Jones M. Chronic Neuropathic Pain: Pharmacological Interventions in the New Millenium - A Theory of Efficacy. International Journal
of Pharmaceutical Compounding
. Jan/Feb 2000; 4(1): 6-15.
2. Jones M. Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance. International Journal of Pharmaceutical
Compounding.
Jan/Feb 2002; 6(1): 4-6.
Algorithm for Chronic Pain (by Medication) Proposed Mode of Action
Therapeutic Category
Medication
Tricyclic Antidepressant
Antidepressant
Gaba Agonist
Muscle Relaxant
Substance P
Analgesic
AMPA-Na Channel Blocker
Anticonvulsant
Gaba Agonist
Benzodiazepine
Alpha II-Agonist
Hypotensive
Tricyclic Antidepressant
Antidepressant
Anti-inflammatory
Corticosteroid
NMDA-Ca Channel Blocker
Antitussive
Anti-inflammatory
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
Supplements
Antiarthritic
Supplements
Antiarthritic
Anti-inflammatory
Tricyclic Antidepressant
Antidepressant
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
Anti-inflammatory
AMPA-Na Channel Blocker
Anesthetic
Supplements
Antoxidant
Mu Agonist
Antidiarrheal
Supplements
Analgesic
Supplements
Analgesic
AMPA-Na Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Muscle Relaxant
Supplements
Muscle Relaxant
Supplements
Muscle Relaxant
Mu Agonist
Calcium Channel Blocker
Hypotensive
Supplements
Anti-inflammatory
Mu Agonist
Increase Blood Flow
Hemorheologic
Alpha II-Agonist
Hypotensive
Anti-inflammatory
Supplements
Analgesic
Supplements
Analgesic Synergy
Notes: Ketamine 5%, Gabapentin 10%, Clonidine 0.2%, Baclofen 2% is standard starting regimen. (Formula # 7919)
References:
1. Jones M. Chronic Neuropathic Pain: Pharmacological Interventions in the New Millenium - A Theory of Efficacy. International Journal of
Pharmaceutical Compounding
. Jan/Feb 2000; 4(1): 6-15.
2. Jones M. Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance. International Journal of Pharmaceutical
Compounding.
Jan/Feb 2002; 6(1): 4-6.
Algorithm for Chronic Pain (by Therapeutic Category) Proposed Mode of Action
Therapeutic Category
Medication
Substance P
Analgesic
Supplements
Analgesic
Supplements
Analgesic
Supplements
Analgesic
Supplements
Analgesic Synergy
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
NMDA-Ca Channel Blocker
Anesthetic
AMPA-Na Channel Blocker
Anesthetic
AMPA-Na Channel Blocker
Anesthetic
Supplements
Antiarthritic
Supplements
Antiarthritic
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
AMPA-Na Channel Blocker
Anticonvulsant
Tricyclic Antidepressant
Antidepressant
Tricyclic Antidepressant
Antidepressant
Tricyclic Antidepressant
Antidepressant
Mu Agonist
Antidiarrheal
Supplements
Anti-inflammatory
NMDA-Ca Channel Blocker
Antitussive
Supplements
Antoxidant
Gaba Agonist
Benzodiazepine
Anti-inflammatory
Corticosteroid
Increase Blood Flow
Hemorheologic
Alpha II-Agonist
Hypotensive
Calcium Channel Blocker
Hypotensive
Alpha II-Agonist
Hypotensive
Gaba Agonist
Muscle Relaxant
NMDA-Ca Channel Blocker
Muscle Relaxant
Supplements
Muscle Relaxant
Supplements
Muscle Relaxant
Anti-inflammatory
Anti-inflammatory
Anti-inflammatory
Anti-inflammatory
Mu Agonist
Mu Agonist
Notes: Ketamine 5%, Gabapentin 10%, Clonidine 0.2%, Baclofen 2% is standard starting regimen. (Formula # 7919)
Refernces:
1.Jones M. Chronic Neuropathic Pain: Pharmacological Interventions in the New Millenium - A Theory of Efficacy. International Journal
of Pharmaceutical Compounding
. Jan/Feb 2000; 4(1): 6-15.
2. Jones M. Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance. International Journal of Pharmaceutical
Compounding.
Jan/Feb 2002; 6(1): 4-6.
Algorithm for Chronic Neuropathy
Mode of Action and members of the class (not exhaustive) 1) NMDA-Ca Channel Blocker Ketamine 5-10% in PLO, 10-30mg PO or PR tid regularly + up to q2h prn Orphenadrine 10% in PLO or 100mg PO tid Dextromethorphan 10% in PLO or <400mg/day PO Amantadine 200mg/250-500cc IV over 3 hours once (repeat x1 prn). Anticonvulsant - * Gabapentin 6-10% in PLO tid + up to q2h prn or up to 2-3Gm/day PO *Probably blocks glutamate at the NMDA also Carbamazepine 10% in PLO tid + up to q2h prn or 100mg-200mg PO bid/tid (Max 800mg/day) Antiarrhythmic - Lidocaine 5-10% in PLO tid + up to q2h prn Mexilitine 2% in PLO tid + up to q2h prn Clonidine 0.2% in PLO tid + up to q2h prn MU agonists (MS, Hydrocodone, Oxycodone, etc) (low dose) PO or PLO Mu Agonist also: Loperamide 7% and up PLO 5) GABAb Agonist Baclofen 2% PLO tid + up to q2h prn Non specific GABA agonist - Klonopin 0.5mg-1mg SubL. qhs 6) Tricyclic Antidepressant Desipramine 2-10% in PLO tid + up to q2h prn or 25-100mg PO qHS Amitriptyline 2-10% in PLO tid + up to q2h prn Magnesium: Intracellular Resident NMDA Ca Channel Blocker For Fibromyalgia - Mg/Malic Acid 25/250 mg PO tid For Diabetic Neuropathy - Lipoic Acid 100mg-300mg PO tid Bioflavanoids/citrus 500 to 2000 mg PO tid Nifedipine 2 to 5% PLO tid Or up to 16% for small areas, i.e., toes Alpha-antagonist (I & II) Phentolamine 80mg over 24 hours slow IV one time only! (for organic neuropathy, i.e., pancreatic cancer). 1. Ketamine 10%, Gabapentin 6%, Clonidine 0.2% is standard starting regimen. 2. Add Baclofen 2%, Amitriptyline 2%, Nifedipine, Opioid, Mg as needed. (I.e., use Baclofen specifically in FM patients but also in others and use Amitriptyline in CRPS Type I patients but also in others.) 3. In allodynic Post Herpetic Neuralgia use Ketamine 10% + Bupivacaine 0.5% in a Normal Saline spray to the area, wait 5 to 10 minutes and apply the PLO gel chosen. This spray also has been reported to ease burn pain. 4. Evidence exists for presence of NMDA receptors in the dermal-epidermal junction. AMPA receptors always lie close to NMDA receptors. 5. Evidence exists for the presence of Gabapentin receptors in the periphery. 6. Evidence exists for the presence of adrenergic receptors in the periphery. 7. Evidence exists for the presence of opioid receptors in the periphery.
References:
1. Jones M. Chronic Neuropathic Pain: Pharmacological Interventions in the New Millennium – A Theory of Efficacy. International Journal of Pharmaceutical Compounding. Jan/Feb 2000; 4(1): 6-15. 2. Jones M. Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance. International Journal of Pharmaceutical Compounding. Jan/Feb 2002; 6(1): 4-6.

Source: http://procompounding.com/wp-content/uploads/2013/02/94064_Algorithm_of_NP.pdf

3rd internationl european cngress of tcm

3rd Internationl European Cngress of TCM Brussels, Belgium, 4th & 5th October, 2003 Presentation title: Anorexia nervosa – a study case of mother-daughter relationship in the light of Five Phases Cycle. Author: Henryk Dyczek, Ac.M., D.C., B.Sc. in Chiropractic (Oxford) The strength of Traditional Chinese Medicine (TCM) rests in its diagnosis and treatment protocol, which takes into

New patient form

PLEASE GIVE US YOUR INSURANCE CARD TO BE PHOTOCOPIED Please print clearly Patient’s name: _________________________________________________________ Date: ______________________________________ Address:_______________________________________________________________ Home phone: ________________________________ City: __________________________________________________________________ State:

Copyright © 2011-2018 Health Abstracts